Article info
PDFSpecial communication
An evaluation of the FDA's analysis of the costs and benefits of the graphic warning label regulation
- Correspondence to Professor Frank J Chaloupka, Department of Economics, Institute for Health Research and Policy, University of Illinois at Chicago, Chicago, IL 60608, USA; fjc{at}uic.edu
Citation
An evaluation of the FDA's analysis of the costs and benefits of the graphic warning label regulation
Publication history
- Received October 1, 2014
- Accepted November 28, 2014
- First published December 30, 2014.
Online issue publication
May 13, 2016
Article Versions
- Previous version (13 May 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/